Document Detail


Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity.
MedLine Citation:
PMID:  6572564     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Aclarubicin was given iv every 3 weeks to 21 patients with a variety of solid tumors. Four dose levels were tested: 80, 100, 120, and 140 mg/m2. The median cumulative dose was 270 mg/m2 (range, 80-900). No objective responses were observed. Hematologic toxicity was dose-limiting. All patients experienced moderate to severe gastrointestinal toxicity. Five of 13 patients evaluable for cardiac function showed clinical signs and ECG changes suggestive of cardiac dysfunction. The suggested maximum dose for phase II trials is 120-140 mg/m2 iv given in an intermittent 3-week schedule.
Authors:
K Aabo; S A Mortensen; T Skovsgaard; E Gymoese
Related Documents :
21711094 - Should high-dose interleukin-2 still be the preferred treatment for patients with metas...
16740014 - Decitabine: in myelodysplastic syndromes.
22171214 - Primary squamous cell carcinoma of the liver: an uncommon finding in contrast-enhanced ...
6254684 - Phase ii trial of prednimustine (nsc-134087) in the treatment of small-cell anaplastic ...
21400524 - Lymph node ratio as determined by the 7th edition of the american joint committee on ca...
3677034 - Photodynamic therapy in the management of resistant lower urinary tract carcinoma.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cancer treatment reports     Volume:  67     ISSN:  0361-5960     ISO Abbreviation:  Cancer Treat Rep     Publication Date:  1983 Mar 
Date Detail:
Created Date:  1983-05-27     Completed Date:  1983-05-27     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7607107     Medline TA:  Cancer Treat Rep     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  281-2     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aclarubicin
Adult
Aged
Antibiotics, Antineoplastic / toxicity*
Drug Evaluation
Female
Heart / drug effects*
Humans
Male
Middle Aged
Naphthacenes / administration & dosage,  toxicity
Neoplasms / drug therapy*
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/Naphthacenes; 57576-44-0/Aclarubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous e...
Next Document:  Induction of cytotoxic effector activity in the HL-60 promyelocytic cell line by incubation with pho...